Journal of Pharmacokinetics & Experimental Therapeutics
Open Access

Excretion is a crucial step in the pharmacokinetic process, responsible for the removal of drugs and their metabolites from the body. Once a drug has been absorbed, distributed, and metabolized, excretion helps eliminate it, preventing accumulation that could lead to toxicity or unwanted side effects. The primary routes of excretion are renal, hepatic, pulmonary, and gastrointestinal, with minor pathways including sweat, saliva, and breast milk. Each of these routes plays a distinct role in the elimination of different types of substances, depending on the drug’s properties and its metabolic fate. Renal excretion, which occurs through the kidneys, is the most common route for water-soluble drugs and metabolites. The kidneys filter blood, allowing small molecules to be excreted in urine after processes of filtration, secretion, and reabsorption. Hepatic excretion involves the liver, where drugs undergo metabolism and are excreted into the bile for eventual elimination through feces. This route is particularly important for larger, hydrophobic molecules. Pulmonary excretion is vital for volatile substances like gases and alcohol, which are expelled through the lungs [1]. The gastrointestinal tract also serves as an excretion route, especially for drugs excreted into the bile, which are then eliminated in the feces.

Methodology

Renal excretion

The kidneys are the primary organ responsible for the elimination of most drugs and their metabolites. Renal excretion is a complex process involving filtration, secretion, and reabsorption, and it plays a dominant role in clearing water-soluble substances. The process can be divided into the following steps:

Filtration: The first step occurs in the glomerulus, where blood is filtered. Drugs and their metabolites that are small enough to pass through the glomerular membrane (typically less than 500 Da) are filtered into the renal tubules. The glomerular filtration rate (GFR) determines how quickly substances are filtered from the blood into the urine [2].

Secretion: Active secretion of substances occurs primarily in the proximal convoluted tubule, where specialized transporters actively transport drugs or metabolites from the blood into the urine. This process helps eliminate drugs that are not effectively filtered through the glomerulus.

Reabsorption: In the renal tubules, some drugs and metabolites are reabsorbed back into the bloodstream. This process is influenced by the pH of the urine, the lipid solubility of the substance, and its molecular size. For example, acidic drugs tend to be reabsorbed more in an acidic environment, whereas basic drugs are reabsorbed more efficiently in alkaline urine [3 ].

The efficiency of renal excretion can be affected by various factors, including renal function (as in cases of renal impairment or disease), urine pH, and drug properties like protein binding. For drugs eliminated by the kidneys, renal clearance is a key pharmacokinetic parameter, indicating how much drug is removed from the body per unit of time.

Hepatic excretion

The liver plays a critical role in drug metabolism, but it also contributes to excretion through the biliary system. Drugs and metabolites can be excreted into the bile, from where they are eventually released into the gastrointestinal tract and expelled in feces. Hepatic excretion is particularly important for larger, more hydrophobic molecules that may not be easily eliminated through renal pathways [4].

Biliary excretion: After undergoing hepatic metabolism, drugs are often conjugated to more water-soluble molecules such as glucuronides or sulfates. These conjugates are more easily excreted in bile. Once excreted into the bile, these conjugates can either be eliminated in the feces or reabsorbed into the bloodstream in a process known as enterohepatic circulation. The latter prolongs the drug’s presence in the body, as it can be recirculated and metabolized again [5,6].

Some drugs, particularly those that are poorly absorbed from the gastrointestinal tract, may undergo extensive hepatic excretion. A classic example is the excretion of certain steroid hormones and bile acids. The efficiency of hepatic excretion can be influenced by liver function, bile flow, and the presence of liver disease.

Pulmonary excretion

The lungs are responsible for the excretion of volatile substances, primarily gases and some small, non-polar drugs. This route of excretion is most relevant for gases such as anesthetic agents (e.g., nitrous oxide, halothane) and alcohol (ethanol), which are both absorbed into the bloodstream and then exhaled by the lungs [7]. The mechanism is based on the diffusion of volatile compounds from the blood, where their concentration is higher, to the alveoli, where their concentration is lower.

The excretion of drugs via the lungs is relatively efficient for volatile substances but is less important for most other drugs [8]. Factors influencing pulmonary excretion include blood flow to the lungs, the solubility of the substance in blood, and the concentration gradient between the blood and alveolar air.

Gastrointestinal excretion

Excretion via the gastrointestinal (GI) tract occurs when drugs or their metabolites are eliminated through the feces. Some drugs are directly excreted in the GI tract without undergoing absorption, but this is relatively rare. More often, drugs are metabolized in the liver and then excreted into the bile, as described previously in the hepatic excretion section.

In addition, small amounts of drugs may be excreted into the GI tract via the secretion of the gastrointestinal tract cells or through direct diffusion from the bloodstream into the intestines [9 ]. The excretion via feces can be significant for drugs that have poor absorption and are extensively metabolized in the liver, or drugs that cannot be absorbed back after being excreted into the bile.

Sweat and salivary excretion

Minor routes of drug excretion include sweat and saliva. While these routes contribute minimally to drug elimination, they can still play a role in the excretion of some drugs, especially those with small molecular weights and high lipid solubility. Drugs excreted through sweat or saliva are usually in very low concentrations, and these routes are not considered significant compared to renal, hepatic, and pulmonary excretion.

Nevertheless, the excretion of drugs via sweat and saliva can sometimes lead to side effects such as skin irritation or a bitter taste in the mouth. Additionally, substances like alcohol or certain illicit drugs can be detected in sweat or saliva, leading to their use in drug testing.

Other routes of excretion

There are other minor routes through which drugs may be excreted, including the skin (via hair follicles), tears, and breast milk [10]. For example, certain drugs pass into breast milk and can be ingested by nursing infants, which is an important consideration when prescribing drugs to lactating mothers.

Conclusion

Excretion is a key component of drug elimination and has important implications for drug dosing, therapeutic efficacy, and toxicity. The main routes of excretion—renal, hepatic, pulmonary, and gastrointestinal—each contribute differently depending on the drug's properties and the physiological state of the individual. A thorough understanding of these excretion mechanisms is essential for predicting drug behavior in the body and optimizing pharmacotherapy.

1. Chakraborty A, Jusko WJ (2002) Pharmacodynamic interaction of recombinant human interleukin-10 and prednisolone using in vitro whole blood lymphocyte proliferation. J Pharm Sci 91:1334-1342.

Indexed at, Google Scholar, Crossref

2. Earp J, Krzyzanski W, Chakraborty A, Zamacona MK, Jusko WJ (2004) Assessment of drug interactions relevant to pharmacodynamic indirect response models. J Pharmacokinet Pharmacodyn 31:345-380.

Indexed at, Google Scholar, Crossref

3. Koch G, Schropp J, Jusko WJ (2016) Assessment of non-linear combination effect terms for drug-drug interactions. J Pharmacokinet Pharmacodyn 43:461-479.

Indexed at, Google Scholar, Crossref

4. Zhu X, Straubinger RM, Jusko WJ (2015) Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells. J Pharmacokinet Pharmacodyn 42:477-496.

Indexed at, Google Scholar, Crossref

5. Nanavati C, Mager DE (2017) Sequential Exposure of Bortezomib and Vorinostat is Synergistic in Multiple Myeloma Cells. Pharm Res 34:668-679.

Indexed at, Google Scholar, Crossref

6. Zimmer A, Katzir I, Dekel E, Mayo AE, Alon U (2016) Prediction of multidimensional drug dose responses based on measurements of drug pairs. Proc Nat Acad Sci 113:10442-10447.

Indexed at, Google Scholar, Crossref

7. Castiglione F, Pappalardo F, Bernaschi M, Motta S (2007) Optimization of HAART with genetic algorithms and agent-based models of HIV infection. Bioinformatics 23:3350-3355.

Indexed at, Google Scholar, Crossref

8. McLeod HL (1998) Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol 45:539-544.

Indexed at, Google Scholar, Crossref

9. Ma J, Verweij J, Planting AS, Kolker HJ, Loos WJ, et al. (1996) Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes. Cancer Chemother Pharmacol 37:382-384.

Indexed at, Google Scholar, Crossref

10. Ando M, Saka H, Ando Y, Minami H, Kuzuya T, et al. (2005) Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences. Cancer Chemother Pharmacol 55:552-558.

Indexed at, Google Scholar, Crossref